Search results
Results from the WOW.Com Content Network
The newest 5-HT 3 inhibitor, palonosetron (Aloxi), also prevents delayed nausea and vomiting, which can occur during the 2–5 days after treatment. Since some patients have trouble swallowing pills, these drugs are often available by injection, as orally disintegrating tablets, or as transdermal patches.
Rolapitant is used in combination with other antiemetic (anti-vomiting) agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. [1]
Cancer and nausea are associated in about fifty percent of people affected by cancer. [1] This may be as a result of the cancer itself, or as an effect of the treatment such as chemotherapy, radiation therapy, or other medication such as opiates used for pain relief. About 70–80% of people undergoing chemotherapy experience nausea or vomiting.
Palonosetron, sold under the brand name Aloxi, is a medication used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). [2] [4] [5] It is a 5-HT 3 antagonist. [2] [4] [5] Palonosetron is administered intravenously, [6] or as a single oral capsule. [7] It has a longer duration of action than other 5-HT 3 antagonists.
The discovery of neurokinin 1 (NK 1) receptor antagonists was a turning point in the prevention of nausea and vomiting associated with cancer chemotherapy. [4] An example of a drug in this class is aprepitant. Chemotherapy-induced emesis appears to consist of acute and delayed phases.
And in studies conducted on another popular weight loss drug called terzepatide (aka, Mounjaro), 5.7 percent of patients reported experiencing hair loss versus less than 1 percent on a placebo. So ...
Clinical trials suggest that it is more effective than other 5-HT 3 antagonists in preventing delayed CINV (nausea and vomiting that occur more than 24 hours after the first dose of chemotherapy). [15] It is taken once daily. Dolasetron was first mentioned in the literature in 1989. [16]
Nausea and diarrhea are common with weight loss injections. Rarer (but more serious) health risks include kidney issues and pancreatitis. All medications have potential side effects.